MedTrace Logo

Anti-CD7 CAR-T Cell Therapy for Relapse and Refractory CD7 Positive T Cell Malignancies

NCT05290155 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 14

Last updated 2025-06-06

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety and efficacy of CAR T cell treatment targeting CD7 in patients with relapsed or refractory CD7 positive T-cell hematological maliganacies

Conditions

  • T Lymphoblastic Leukemia/Lymphoma
  • T-cell Acute Lymphoblastic Leukemia
  • Peripheral T Cell Lymphoma
  • Angioimmunoblastic T-cell Lymphoma
  • Anaplastic Large Cell Lymphoma

Interventions

DRUG

anti-CD7 CAR-T cells

Administration with anti-CD7 CAR-T cells in the relapsed/refractory T cell hematological malignancy patients

Sponsors & Collaborators

  • Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine

    lead OTHER

Principal Investigators

  • Xianmin G Song, M.D. · Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
14 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-05-04
Primary Completion
2024-08-01
Completion
2025-05-01

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05290155 on ClinicalTrials.gov